PartnershipJun 4, 2026, 08:01 AM
Arvinas Joins Michael J. Fox Foundation LRRK2 & PPMI Programs
AI Summary
Arvinas, Inc. announced its participation in the LRRK2 Investigative Therapeutics Exchange (LITE) program and the Parkinson’s Precision Medicine Initiative (PPMI), both backed by The Michael J. Fox Foundation. This collaboration will support the advancement of ARV-102, Arvinas' investigational PROTAC designed to target and degrade LRRK2 for potential treatment of neurodegenerative diseases like Parkinson's and progressive supranuclear palsy (PSP). The initiatives aim to deepen understanding of LRRK2 biology and accelerate therapeutic development through collaborative research and shared resources.
Key Highlights
- Arvinas joined the LRRK2 Investigative Therapeutics Exchange (LITE) program.
- Arvinas joined the Parkinson’s Precision Medicine Initiative (PPMI).
- Both programs are supported by The Michael J. Fox Foundation for Parkinson’s Research.
- Participation aims to advance ARV-102, an investigational PROTAC targeting LRRK2.
- ARV-102 is being developed for neurodegenerative diseases, including Parkinson’s disease and PSP.
- LITE supports the development of therapeutic approaches targeting LRRK2.
- PPMI is an international research effort to advance understanding of Parkinson’s disease.
- ARV-102 is currently in a Phase 1 clinical trial for Parkinson’s disease.
Price Impact
More from ARVN